Polymorphisms of pesticide-metabolizing genes in children living in intensive farming communities

Gómez-Martín, Antonio; Hernández, Antonio F.; Martínez-González, Luis Javier; Gónzalez-Alzaga, Beatriz; Rodríguez‐Barranco, Miguel; López-Flores, Inmaculada; Aguilar-Garduño, Clemente; Lacasaña, Marina

doi:10.1016/j.chemosphere.2015.07.079

Cited by 37 publications

(20 citation statements)

References 37 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were collected in tubes containing ethylenediaminetetraacetic acid (LPUH) and samples of buccal mucosa cells (SCUH) and stored at -20°C. For DNA extraction, the QuickGene DNA blood kit S (Fujifilm, Düsseldorf, Germany) was used in LPUH; the DNA extraction procedure in SCUH was performed according to the method previously published by Freeman et al [ 25 ], with a number of modifications described by Gómez-Martín A. et al [ 26 ]. KASPar® (KBiosciences, Hoddesdon, UK), and TaqMan® (Applied Biosystems, Foster City, USA) technologies were used for genotyping.…”

Section: Methodsmentioning

confidence: 99%

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

Tong¹,

Dávila-Fajardo

Borobia

et al. 2016

PLoS ONE

Self Cite

View full text Add to dashboard Cite

There is a strong association between genetic polymorphisms and the acenocoumarol dosage requirements. Genotyping the polymorphisms involved in the pharmacokinetics and pharmacodynamics of acenocoumarol before starting anticoagulant therapy would result in a better quality of life and a more efficient use of healthcare resources. The objective of this study is to develop a new algorithm that includes clinical and genetic variables to predict the most appropriate acenocoumarol dosage for stable anticoagulation in a wide range of patients. We recruited 685 patients from 2 Spanish hospitals and 1 primary healthcare center. We randomly chose 80% of the patients (n = 556), considering an equitable distribution of genotypes to form the generation cohort. The remaining 20% (n = 129) formed the validation cohort. Multiple linear regression was used to generate the algorithm using the acenocoumarol stable dosage as the dependent variable and the clinical and genotypic variables as the independent variables. The variables included in the algorithm were age, weight, amiodarone use, enzyme inducer status, international normalized ratio target range and the presence of CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), VKORC1 (rs9923231) and CYP4F2 (rs2108622). The coefficient of determination (R2) explained by the algorithm was 52.8% in the generation cohort and 64% in the validation cohort. The following R2 values were evaluated by pathology: atrial fibrillation, 57.4%; valve replacement, 56.3%; and venous thromboembolic disease, 51.5%. When the patients were classified into 3 dosage groups according to the stable dosage (<11 mg/week, 11–21 mg/week, >21 mg/week), the percentage of correctly classified patients was higher in the intermediate group, whereas differences between pharmacogenetic and clinical algorithms increased in the extreme dosage groups. Our algorithm could improve acenocoumarol dosage selection for patients who will begin treatment with this drug, especially in extreme-dosage patients. The predictability of the pharmacogenetic algorithm did not vary significantly between diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

Tong¹,

Dávila-Fajardo

Borobia

et al. 2016

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…UA exhibits 1 or more of 3 principal presentations: [1] rest angina (usually lasting >20 minutes), [2] new-onset (<2 months previously) severe angina, and [3] a crescendo pattern of occurrence (increasing in intensity, duration, frequency, or any combination of these factors).Non fatal stroke: neurological deficit of 24 hours or more with confirmation by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

“…For genotyping, DNA is isolated from saliva sample using standard procedures according to the method detailed in Freeman et al [2], and in other protocol with some modifications described by Gomez-Martín et al [3].…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent

et al. 2017

Self Cite

View full text Add to dashboard Cite

This article contains data related to the research article entitled “Results of genotype–guided antiplatelet therapy in patients undergone percutaneous coronary intervention with stent” (J. Sánchez-Ramos, C.L. Dávila-Fajardo, P. Toledo Frías, X. Díaz Villamarín, L.J. Martínez-González, S. Martínez Huertas, F. Burillo Gómez, J. Caballero Borrego, A. Bautista Pavés, M.C. Marín Guzmán, J.A. Ramirez Hernández, C. Correa Vilches, J. Cabeza Barrera, 2016) (1). This data article reports, for the first time, about the non-randomized clinical trial protocol that check if CYP2C19/ABCB1 genotype–guided strategy in which the choice of antiplatelet therapy is based on the genetic test, reduces the rates of cardiovascular events and bleeding compared to a non-tailored strategy in patients undergone percutaneous coronary intervention (PCI) with stent. The data included in this article are: design and setting of the study, study population, inclusion and exclusion criteria, definition of the intervention, objectives, variables (baseline characteristics and during the follow-up), study procedures, collection and treatment of the biological sample, genotyping, withdrawal criteria, sample size, statistic analysis, ethical aspects, information sheet and consent form. The authors confirm that this study has been registered in Eudra CT (Eudra CT: 2016-001294-33).

show abstract

“…This test is an adaptation performed by (Martín et al, 2015), which includes 40 actions that the subject must perform using one side of the body. Table 1 shows these actions of the laterality test.…”

Section: Lateral Test Of the Neuropsychologicalmentioning

confidence: 99%

Laterality and pre-reading processes at an early age

Cedeño

Zambrano

Rengifo³

et al. 2019

ijhs

View full text Add to dashboard Cite

Preschool ages are vital to the processes related to the acquisition and consolidation phases of defined laterality in children who will take advantage of this dimension to obtain favorable results in their academic performance and neuropsychological development. In this research, we intend to analyze the relationship between laterality at an early age and the construction of pre-reading processes through application programs and specific tests (such as the Martin Lobo adapted test); The sample of the same corresponds to 10 children attending the Children's Center of Good Living "Caritas Felices". In conclusion, it managed to demonstrate the impact of stimulation on interhemispheric interconnection and pre-reading processes. As part of the intervention program, both educators of the children's center and parents pledged to participate in a laterality training program in order to prevent and intervene in subsequent neuropsychological problems.

show abstract

Polymorphisms of pesticide-metabolizing genes in children living in intensive farming communities

Cited by 37 publications

References 37 publications

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent

Laterality and pre-reading processes at an early age

Contact Info

Product

Resources

About